Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03963414 · ClinicalTrials.gov registry record · Phase 1
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03963414: Clinical Trial Phase 1 study, sponsored by University of Nebraska.
NCT03963414 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03963414, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
Primary Outcome
Evaluate the safety and tolerability profile of durvalumab + tremelimumab in combination with carboplatin and etoposide in ES-SCLC and PS2. Adverse events with a severity grade of 3 or higher per CTCAE guidelines will be used to assess this outcome.
Interventions
- COMBINATION_PRODUCT Durvalumab + Tremelimumab in combination with carboplatin and etoposide
- COMBINATION_PRODUCT Durvalumab in combination with carboplatin and etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 1 |
Why NCT03963414 stopped before completion
NCT03963414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Durvalumab + Tremelimumab in combination with carboplatin and etoposide is the first listed.
NCT03963414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03963414 about?
NCT03963414 is a clinical study titled "A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC". This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
What is the current status of trial NCT03963414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-09-25. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT03963414?
The interventions under investigation include: Durvalumab + Tremelimumab in combination with carboplatin and etoposide (COMBINATION_PRODUCT), Durvalumab in combination with carboplatin and etoposide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03963414?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03963414's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI